|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cardioprotection by resveratrol:a human clinical trial in patients with stablecoronary artery disease 显示文摘 | Magyar K Halmosi R Palfi A | 2012 | Clin Hemorheol Microcirc2012，50，3： | 1 |
| 2 | Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound 显示文摘 | Deres P Halmosi R Toth A | 2005 | J Cardiovasc Pharmacol2005，45，1： | 1 |
| 3 | In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine 显示文摘 | E Horvath B Marton Z Halmosi R | 2002 | Clin Neuropharmacol2002，25，1： | 1 |
| 4 | Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound显示文摘 | Halmosi R Toth A | 2005 | J Cardiovasc Pharmacol2005，45，： | 1 |
| 5 | Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease 显示文摘 | Magyar K Halmosi R Palfi A | 2012 | Clin Hemorheol Microcire2012，50，3： | 1 |
| 6 | Prevention of doxorubicin- induced acute cardiotoxicity by an experimental antioxidant compound显示文摘 | Deres P Halmosi R Toth A | 2005 | J Cardiovasc Pharmaco12005，45，1： | 1 |
| 7 | In vitro antioxidantproperties ofpentoxifylline,piraeetam,and vinpocetine显示文摘 | Horvath B Marton Z Halmosi R | | 0，，01： | 1 |
| 8 | From hypertension to heart failure显示文摘Hypertension is an increasing health problem worldwide especially among the elderly.Its therapeutical importance is indicated by the caused organ damages like hypertensive heart disease(HHD) and heart failure with the subsequent higher morbidity and mortality in the population.In HHD ventricular hypertrophy develops as a compensatory mechanism for pressure overload but as the left ventricular compliance decreases,the process can transform into heart failure with firstly preserved and then into reduced ejection fraction(HFp EF,HFr EF).The main characteristics of underlying mechanisms involve cardiomyocyte growth,vessel changes,increased collagen production in all of which several mechanical stress induced neurohumoral agents,signal transduction pathways are involved.According to the new ESC and AHA guidelines five main groups of antihypertensive agents can be applied for decreasing blood pressure and for the prevention of organ damages.Occasionally,patients are not able to tolerate antihypertensive medication because of side effects,drug intolerance or interactions thus it is more difficult to reach the target blood pressure values.Therefore there are several efforts to complete the existing therapeutical possibilities against the development of organ damages like inhibition of Rho/ROCK pathway(e.g.,statins),regulation of ROS formation,influence on mitochondrial biogenesis and enhancing recombinant adenovirus hepatocyte growth factor gene.Hypertension induced oxidative stress causes DNA breaks producing the activation of nuclear poly(ADP-ribose) polymerase-1(PARP) enzyme that leads to energy depletion and unfavorable modulation of different kinase cascades.PARP activation promotes the development of HHD,and its transition to heart failure.Therefore inhibition of PARP-enzyme offers another new therapeutical approach among hypertensive patients.The purpose of this review is to give a comprehensive summary about the most significant mechanisms in HHD and an insight into new potential therapies. | Klara Magyar Roland Gal Adam Riba Tamas Habon Robert Halmosi Kalman Toth | 2015 | World Journal of Hypertension2015，5，2： | 1 |
| 9 | In vitro antioxidant properties of pentoxifylline,piracetam,and vinpocetine显示文摘 | Horvath B Marton Z Halmosi R | | 0，，01： | 1 |
| 10 | Cardiopmtection by res- veratrol : a human clinical trial in patients with stable coronary ar- tery disease 显示文摘 | Magyar K Halmosi R Palfi A | 2012 | Clin Hemorheol Micmcirc2012，50，3： | 1 |
| 11 | In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine 显示文摘 | Horvath B Marton Z Halmosi R | 2002 | Clin Neuropharma- col2002，25，1： | 1 |
| 12 | Prevention of doxorubicin induced acute cardiotoxicity by an experimental antioxidant compound显示文摘 | Deres P Halmosi R Toth A | | 0，，01： | 1 |
| 13 | Prevention of doxorubi-cin-induced acute cardiotoxicity by an experimental antioxidantcompound显示文摘 | DERES P HALMOSI R TOTH A | 2005 | J Cardiovasc Pharmacol2005，45，1： | 1 |
| 14 | In vitro antioxidant properties of pentoxifylline,piracetam,and vinpocetine显示文摘 | Horvath B Marton Z Halmosi S | 2002 | Clin Neuropharmacol2002，25，1： | 1 |
| 15 | Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound显示文摘 | Deres P Halmosi R Toth A | 2005 | J Cardiovasc Pharmacol2005，45，1： | 1 |
| 16 | Prevention of doxorubicin-induced acute cardio toxicity by an experimental antioxidant com-pound显示文摘 | Deres P Halmosi R Toth A | 2005 | J Cardiovasc Pharmacol2005，45，1： | 1 |
| 17 | Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease显示文摘 | K. Magyar R. Halmosi A. Palfi G. Feher L. Czopf A. Fulop I. Battyany B. Sumegi K. Toth E. Szabados | 2012 | Clinical Hemorheology and Microcirculation2012，，3： | 1 |
| 18 | In vitro antioxidant properties of pentoxifylline, piracentam and vincamine显示文摘 | Horvath B Marton Z Halmosi R | 2002 | Clin Neuropharmacol2002，25，1： | 1 |
| 19 | In vitro antioxi- dant properties of pentoxifylline, piraeentam and vcamine 显示文摘 | Horvath B Marton Z Halmosi R | 2002 | Clin Neuropharmacol2002，25，1： | 1 |
| 20 | In vitro antioxidant properties of pentoxifylline,piracetam,and vinpocetine显示文摘 | Horvath B Marton Z Halmosi R | 2002 | Clin Neuropharmacol2002，25，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员